Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, June 5, 2025, at 11:05 a.m. EDT. The presentation will be accessible through a live webcast on the 'Events & Presentations' section of Immunocore's website, with a replay available for a limited time after the event.
Immunocore Holdings plc (Nasdaq: IMCR), un'azienda biotecnologica in fase commerciale specializzata nello sviluppo di farmaci immunomodulatori per il cancro, le malattie infettive e autoimmuni, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Sanit脿 Jefferies 2025. Il management dell'azienda parteciper脿 a una conversazione informale gioved矛 5 giugno 2025 alle 11:05 EDT. La presentazione sar脿 disponibile tramite webcast in diretta nella sezione 'Eventi e Presentazioni' del sito web di Immunocore, con una replica accessibile per un periodo limitato dopo l'evento.
Immunocore Holdings plc (Nasdaq: IMCR), una empresa biotecnol贸gica en etapa comercial enfocada en desarrollar medicamentos inmunomoduladores para el c谩ncer, enfermedades infecciosas y autoinmunes, ha anunciado su participaci贸n en la pr贸xima Conferencia Global de Salud Jefferies 2025. La direcci贸n de la empresa participar谩 en una charla informal el jueves 5 de junio de 2025 a las 11:05 a.m. EDT. La presentaci贸n estar谩 disponible a trav茅s de una transmisi贸n en vivo en la secci贸n 'Eventos y Presentaciones' del sitio web de Immunocore, con una repetici贸n disponible por tiempo limitado despu茅s del evento.
Immunocore Holdings plc (Nasdaq : IMCR), une soci茅t茅 biotechnologique en phase commerciale sp茅cialis茅e dans le d茅veloppement de m茅dicaments immunomodulateurs pour le cancer, les maladies infectieuses et auto-immunes, a annonc茅 sa participation 脿 la prochaine Conf茅rence mondiale Jefferies sur la sant茅 en 2025. La direction de l'entreprise participera 脿 une discussion informelle le jeudi 5 juin 2025 脿 11h05 EDT. La pr茅sentation sera accessible via un webcast en direct dans la section 芦 脡v茅nements & Pr茅sentations 禄 du site web d'Immunocore, avec une rediffusion disponible pendant une dur茅e limit茅e apr猫s l'茅v茅nement.
Immunocore Holdings plc (Nasdaq: IMCR), ein Biotechnologieunternehmen in der kommerziellen Phase, das sich auf die Entwicklung immunmodulierender Medikamente gegen Krebs, Infektionskrankheiten und Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference 2025 angek眉ndigt. Das Management des Unternehmens wird am Donnerstag, den 5. Juni 2025, um 11:05 Uhr EDT an einem Fireside-Chat teilnehmen. Die Pr盲sentation wird 眉ber einen Live-Webcast im Bereich 鈥濫vents & Presentations鈥� auf der Website von Immunocore zug盲nglich sein, mit einer zeitlich begrenzten Wiederholung nach der Veranstaltung.
Positive
None.
Negative
None.
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025)聽) (鈥淚mmunocore鈥� or the 鈥淐ompany鈥�), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference.
2024 Jefferies Global Healthcare Conference Fireside Chat: Thursday, June 5, 2025, at 11:05 a.m. EDT
The presentation will be webcast live and can be accessed by visiting 鈥楨vents & Presentations鈥�, under 鈥楨vents鈥�, via the 鈥業nvestors鈥� section of Immunocore鈥檚 website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX 鈥� Immune mobilizing monoclonal TCRs Against X disease 鈥� designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs鈥� in oncology, infectious diseases, and autoimmune diseases. The Company鈥檚 most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Clayton Robertson / Morgan Warenius T: +1 (215) 384-4781 E:
FAQ
When is Immunocore (IMCR) presenting at the 2025 Jefferies Healthcare Conference?
Immunocore will present at the conference on Thursday, June 5, 2025, at 11:05 a.m. EDT through a fireside chat format.
How can investors access Immunocore's (IMCR) presentation at the Jefferies Conference?
Investors can access the live webcast through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website at www.immunocore.com.
What type of medicines does Immunocore (IMCR) develop?
Immunocore develops immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune diseases.
Will there be a replay available of Immunocore's (IMCR) Jefferies Conference presentation?
Yes, a replay of the presentation will be made available for a limited time after the event on Immunocore's website.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
